Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Canine cancer vaccine trial gets underway
“The vaccine may not be effective, but this is probably the only approach to this type of vaccine, so we feel we have to try it." Professor Stephen Johnston.
Study is the largest of its kind in the history of veterinary medicine

One of the largest clinical trials conducted to date for canine cancer is currently underway in the United States.

Researchers from the University of California, Colorado State University and the University of Wisconsin are participating in the Vaccination Against Canine Cancer Study (VACCS trial) to assess a new vaccine strategy for the prevention, rather than the treatment, of cancer in dogs.

Scientists hope that, if the vaccine works, it could provide important justification for exploring a similar approach in humans.

David Vail, a professor and board-certified oncologist at the University of Wisconsin–Madison School of Veterinary Medicine, said: “We’re testing a totally novel way of creating an anti-cancer immune response. The holy grail would be to prevent cancer as opposed to waiting for it to start and then treating it.”

The preventative cancer vaccine works similarly to how an influenza vaccine supports the body’s ability to fight flu. I.e., “to have the immune system primed such that if a cancer cell develops, it will attack,” said Vail.  

With over 800 dogs participating in the trial, the study is the largest of its kind conducted to date, and in the history of veterinary medicine.

Professor Stephen Johnston from Arizona State University, who developed the vaccine, said: “The vaccine may not be effective, but this is probably the only approach to this type of vaccine, so we feel we have to try it. The implications of success would be quite large — for dogs and people.”

The vaccine is designed to target some 30 abnormal proteins found on the surface of cancer cells. These proteins, which are the result of incorrectly-coded RNA, are generally only found in patients with cancer.

Scientists hope that by vaccinating healthy patients with these proteins, together with a substance that stimulates an immune response, the vaccine could serve as a universal defender against cancer by “turning on” the immune system.

The vaccine will target several cancers common to dogs, including lymphoma, osteosarcoma, hemangiosarcoma and mastocytomas.

Participating dogs must be aged between six and 10 years, with no previous history of cancer. The dogs will receive either a series of inoculations or a placebo and will live at home while being checked two-to-three times a year, for five years after enrolment.

Researchers have agreed to cover the costs associated with diagnostics and treatment of any cancers that dogs develop, whether or not they are receiving a vaccine or placebo.

Become a member or log in to add this story to your CPD history

Nominations open for National Cat Awards 2020

News Story 1
 UK charity Cats Protection has announced that cat owners can nominate their pets for the National Cat Awards 2020 starting today.

The awards take place annually, celebrating heart warming stories of the positive impact that cats have on their owners. Cat owners have until Thursday 12 March to submit their nominations through the Cats Protection website. 

Click here for more...
News Shorts
Vetpol recognised as suitable body to maintain register of SQPs

Online community Vetpol has been recognised by the Veterinary Medicines Directorate (VMD) as a suitable organisation to maintain a register for suitably qualified persons (SQPs).

SQPs are professionally qualified to prescribe and supply veterinary medicines classified as POM-VPS and NFA-VPS such as flea and worming treatments as well as advise on their safe and effective use.

Vetpol is now the third body approved to maintain a register of SQPs, along with Animal Medicines Training Regulatory Authority (AMTRA) and VetSkill.

Recognition from the VMD means that Vetpol has successfully demonstrated its ability to fulfil the requirements of the Veterinary Medicines Regulations.